New Jersey is currently home to 1652 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213)
NCT04821791
Recruiting
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2021
Locations: New Jersey Hematology Oncology Associates Llc, Brick, New Jersey
Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Register for Updates
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04816578
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: New Jersey Hematology Oncology Associates Llc, Brick, New Jersey
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Hassman Research Institute, Berlin, New Jersey
Conditions: Schizophrenia
Register for Updates
Taltz in Combination With Enstilar for Psoriasis
NCT04372277
Recruiting
Enstilar in combination with Taltz for plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Duobrii in Combination With Biologics
NCT04119102
Recruiting
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
NCT04347473
Recruiting
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2020
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03827876
Recruiting
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2019
Locations: Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
NCT03392337
Recruiting
A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2019
Locations: Elise Nelson, East Windsor, New Jersey
Conditions: Psoriasis
Register for Updates